Ipsen Partners with Dassault Systemes to Develop Advanced Programs using the 3DEXPERIENCE Platform
FREMONT, CA: Dassault Systèmes, a software company that develops 3D design, 3D digital mock-up, and product lifecycle management solutions and Ipsen, a global specialty-driven pharmaceutical group recently announced entering into a partnership for developing advanced and creative programs using the 3DEXPERIENCE platform.
By selecting the “Designed to Cure” industry solution experience from Dassault Systèmes, Ipsen looks to speed up and simplify its research and development (R&D) transformation and discovery of new therapeutic solutions. The Designed to Cure platform offers data integration, collaboration, knowledge driven innovation and predictive analytics, which will provide Ipsen high quality and accessible scientific knowledge across the organization. The platform strengthens decision-making through real-time views across the lifecycle of therapeutics innovation.
Furthermore, the platform will provide modeling and simulation capabilities to capture a complete view of the dysregulations associated to diseases as well as improve and shorten the identification of higher quality drug candidates. The Designed to Cure platform also accelerates drug design and development by combining in silico and physical experiments, while integrating Quality-by-Design principles to comply with regulations.
Simulation has also long been recognized for the integral role it plays in high-risk industries. In the healthcare industry it is the significant factor to cost-effective and competitive management of healthcare operations. In essence, this collaboration is focused on optimizing the R&D processes of Ipsen’s multi-disciplinary teams located in the core of the leading biotechnological and life sciences hubs worldwide.
“After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools,” said Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, Ipsen. “Ipsen as a key scientific partner has ‘open innovation’ in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care.”
“The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before,” said Jean Colombel, Vice President, Life Sciences Industry, Dassault Systèmes. “Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences.”
By James Seevers, CIO & GM, Toyoda Gosei
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Bruce. D. Smith, SVP & CIO, Information Systems, Advocate...
By Adrian Mebane, VP-Global Ethics & Compliance, The Hershey...
By Graham Welch, Director-Cisco Security, Cisco
By Michael Watkins, Senior Product Director, Global Knowledge
By Bernd Schlotter, President of Services, Unify
By Patrick Hale, CIO, VITAS Healthcare
By Steve Bein, VP-GIS, Michael Baker International
By Jason Alan Snyder, CTO, Momentum Worldwide
By Mike Morris, CIO, Legends
By Louis Carr, Jr., CIO, Clark County
By Bill Dow, SVP and General Manager of Business Solutions,...
By Jim Whitehurst, CEO, Red Hat
By Darren Cockrel, CIO, Coyote Logistics, a UPS Company...
By Nathan Johnson, SVP and CIO, Werner Enterprises [NASDAQ:...
By David Tamayo, CIO, DCS Corporation
By Neil Hampshire, CIO, ModusLink Global Solutions, Inc....